CERENOME, INC.

CERENOME, INC. is a U.S. healthcare company that develops and sells precision diagnostics and targeted radiopharmaceuticals for cancers affecting the central nervous system (CNS). The company operates through its wholly owned subsidiary, CNSide Diagnostics, LLC, which focuses on developing and commercializing proprietary laboratory-developed tests. One such test is CNSide®, designed to detect tumor cells that have spread to the central nervous system in patients with carcinomas and melanomas. In the radiopharmaceuticals sector, CERENOME, INC.'s primary candidate is rhenium (186 Re) obisbemeda. This treatment is specifically developed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC). It is delivered directly and locally using approved standard-of-care tissue access methods like convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The company also has an acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188 RNL-BAM), which is designed to treat various solid organ cancers, including primary and secondary liver cancers, through intra-arterial injection. CERENOME, INC. aims to overcome the limitations of traditional radiation therapy, such as long treatment durations, damage to healthy tissue, and insufficient radiation delivery. The company's radioactive drug formulations, medical devices, and therapeutic candidates are designed to deliver safe and effective radiation doses directly to tumors, potentially in a single treatment. This is achieved through innovative drug formulation approaches, including encapsulating radionuclides like rhenium isotopes within nanoliposomes and microspheres. These formulations are intended to increase patient-absorbed radiation doses and extend retention times, ensuring that the isotope clears after significant and essentially complete radiation decay, which contributes to less normal tissue/organ exposure and improved safety margins.